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Abstract
Octreotide is a widely used synthetic somatostatin analogue that significantly improves the management of
neuroendocrine tumours (NETs). Octreotide acts through somatostatin receptors (SSTRs). However, the molecular
mechanisms leading to successful disease control or symptom management, especially when SSTRs levels are low, are
largely unknown. We provide novel insights into how octreotide controls NET cells. CNDT2.5 cells were treated from 1 day
up to 16 months with octreotide and then were profiled using Affymetrix microarray analysis. Quantitative real-time PCR
and western blot analyses were used to validate microarray profiling in silico data. WST-1 cell proliferation assay was applied
to evaluate cell growth of CNDT2.5 cells in the presence or absence of 1 mM octreotide at different time points. Moreover,
laser capture microdissected tumour cells and paraffin embedded tissue slides from SI-NETs at different stages of disease
were used to identify transcriptional and translational expression. Microarrays analyses did not reveal relevant changes in
SSTR expression levels. Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho
GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15),
TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Furthermore,
these novel genes were expressed in tumour tissues at transcript and protein levels. We suggest that octreotide may use a
potential novel framework to exert its beneficial effect as a drug and to convey its action on neuroendocrine cells. Thus, six
novel genes may regulate cell growth and differentiation in normal and tumour neuroendocrine cells and have a role in a
novel octreotide mechanism system.
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Introduction
Neuroendocrine tumours (NETs) are rare cancers that can
affect different parts of the body. Gastrointestinal (GI) NETs
originate from enterochromaffin (EC) cells, which are sparse
neuroendocrine cells disseminated throughout the GI tract [1,2].
A subgroup of GI-NETs are small intestine NETs (SI-NETs). A
recent and detailed WHO classification for GI-NETs is available
in a recent paper [3].
The primary SI-NET is often small and asymptomatic.
Therefore, diagnosis and treatment may be delayed by several
years, during which metastases can form. Radical surgical
resection alone can be curative in patients with early stage disease.
However, most patients present advanced disease at the time of
diagnosis [4]. Thus, the current treatments of metastasized SI-
NETs aim at controlling tumour growth and hormonal secretion
by using mainly somatostatin analogues (SSAs), interferon alpha
and more recently everolimus [5,6,7,8].
Several earlier studies reported that SSAs exert their effects by
binding to SSTRs. Five genes SSTR1-SSTR5 encode five receptors
named SSTR1 to SSTR5 respectively. They signal and activate
cellular and molecular mechanisms leading to either successful
therapy or acquired resistance to the drugs [9,10]. Octreotide
(SandostatinH) was the first SSA commercially available. In
addition, it has high affinity for SSTR2 and moderate affinity
for SSTR3 and SSTR5 [11]. SSAs have long been used to treat
NETs. Somatostatin is a natural growth-hormone-releasing
inhibiting factor produced in the hypothalamus, which exerts its
effects through high-affinity to somatostatin receptors (SSTRs).
These receptors are G coupled protein receptors and elicit cellular
responses through second-messenger systems [12]. The introduc-
tion of octreotide, the first SSA in 1987 and later novel SSAs
resulted in NETs symptom management. However, their capacity
to inhibit tumour growth has been seriously debated for a long
time. The first performed placebo-controlled, double-blinded,
phase IIIB study in patients with well-differentiated metastatic
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e48411
midgut NETs addressed the hypothesis that octreotide-lanreotide
(LAR) prolongs time to tumour progression and survival. The
study concluded that octreotide-LAR significantly lengthens time
to tumour progression compared to placebo in patients with
functionally active and inactive metastatic midgut NETs [13]. The
conclusions of the study have been debated due to its design and
the number of patients included [14,15]. Nevertheless, clinical
results confirmed that octreotide and lanreotide provide in
addition to their suppression of carcinoid syndrome, antitumour
benefits in terms of tumour cell growth control [13]. In summary,
somatostatin analogs (including octreotide and lanreotide) have
been indicated for the relief of the symptoms of flushing, diarrhea,
and wheezing associated with secretory neuroendocrine tumors
(NETs). Recently, it has been suggested that somatostatin analogs
may provide direct and indirect antitumor effects in secretory and
nonsecretory NETs in addition to symptom control in secretory
NETs and more findings have been explored about the octreotide
anti-angiogenic role. However, many aspects of octreotide control
on tumour growth are still largely unclear [16,17,18].
For instance, it is still not known where octreotide can reduce
cell growth in absence of a SSTR pathway. However, the
mechanism that triggers resistance to octreotide has not been
identified. Recently, it has been reported that long-term
treatments with SSAs, such as octreotide, may switch NET cells
to be static in growth activating apoptosis or cell cycle arrest at G1
[19]. However, clinical transposition of the results produced in vitro
is difficult [20]. This finding suggests and supports the idea that
SSAs may use more complex alternative mechanisms, which have
not been fully addressed and deserve further investigation.
Although the number of cell lines available from SI-NETs is
limited and they cannot fully mimic a malignancy, they can still
broaden our understanding of NET cell biology and serve as tools
for development of novel therapies [21,22,23,24,25,26]. The
present study started by testing five human NET cell lines,
CNDT2.5 [27] and KRJ-1 [28], established from SI-NETs, QGP-
1 from a pancreatic NET [29]; and NCI-H720 and NCI-H727
from lung carcinoids. The molecular basis underlying octreotide
growth and differentiation control of neuroendocrine cells is
elusive and would surely benefit from the establishment of a novel
representative in vitro model.
Affymetrix microarray analyses and quantitative real time PCR
(QRT-PCR) showed that CNDT2.5 has the lowest expression of
SSTR1-5. This made CNDT2.5 a suitable model in vitro for our
analysis. CNDT2.5 cells were treated with octreotide for between
1 week and 16 months. Then genome-wide transcript profiling was
used to compare treated and untreated cells. Results showed that
octreotide had the ability to reduce CNDT2.5 cell growth
persistently and, most importantly, revealed the presence of a
small group of six genes, previously unrelated to octreotide-
induced signaling, which may be involved in cell growth rate
reduction and differentiation of neuroendocrine cells.
Results
Quantitative Real Time PCR (QRT-PCR) Analysis Shows
that CNDT2.5 Express Limited Amount of SSTRs
We calculated copy number of the transcripts of the five
somatostatin receptors (SSTRs 1–5) in five human neuroendocrine
cancer cell lines. To investigate the expression of SSTRs the copy
number of b-actin was used as internal control. The results showed
a varied expression of SSTRs pattern (Figure 1). Based on these
data, CNDT2.5 was selected as a suitable model for subsequent
studies given their profile and levels of SSTR expression.
Octreotide Clearly Reduces the Proliferation Rate of
CNDT2.5 Cells
The CNDT2.5 cell line was used as an in vitro model to
investigate the mechanisms whereby octreotide may alter neuro-
endocrine cell biology. Untreated and octreotide-treated
CNDT2.5 cells were always cultured for the same time period in
the different experiments. To determine the effect of octreotide on
CNDT2.5 cell growth, we measured cell proliferation (metabolic
activity of viable cells) in the absence or presence of 1 mM
octreotide at 1 week, 4, 10 and 16 months using the commercial
WST-1 assay. Octreotide reduces the growth of CNDT2.5 cells as
shown in Figure 2. Briefly, 1 week of treatment produced a 15%
cell growth reduction; 4 months, 26%; 10 months, 46%; and 16
months, 49% of growth reduction. In addition, the growth
Figure 1. SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 gene expression
analysis. SSTR1-5 gene expression analysis was performed by QRT-PCR
on total RNA from five human NET cell lines: CNDT2.5, KRJ-1, QGP-1,
NCI-H720 and NCI-H727. The absolute mRNA copy numbers are
adjusted by b-actin mRNA copy number. Results were plotted using
the 22DDCt method with b-actin expression (set to 1) from each
individual sample as endogenous reference.
doi:10.1371/journal.pone.0048411.g001
Figure 2. CNDT2.5 cells growth in the presence of 1 mM
octreotide was kinetically evaluated. Cells were cultured in the
absence or presence of 1 mM octreotide (oct). WST-1 assay was used to
evaluate cell growth. Cell proliferation ratio for each time point was
converted to a percentage of the mean value relative to CNDT2.5 cells
growth, set to 100%. Plotted results are means 6 SD from triplicate
wells. Significance was calculated by using Two-Way ANOVA followed
by Bonferroni test; comparing with untreated CNDT2.5 cells.
*** = p,0.001.
doi:10.1371/journal.pone.0048411.g002
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capacity was rapidly restored after octreotide withdrawal (Sup-
porting Figure S1).
Transcription Analysis of CNDT2.5 Cells in the Absence or
Presence of Octreotide
To uncover the mechanism of action behind the reduction of
cell growth rate induced by octreotide, CNDT2.5 cells were
cultured for 10 and 16 months in the absence or presence of 1 mM
octreotide. Collected total RNA was profiled using Affymetrix
microarrays and raw data were deposited on NCBI’s GEO
(GSE24358) and EBI’s Array-Express database (E-MTAB-388).
Microarray analysis did not detect a high-fold change in the SSTR
expression (Supporting Table S1). However, marked changes in
expression of a number of genes in response to octreotide
treatment were detected by the arrays. Twenty-five genes were
reported as significantly informative by FARMS algorithm and
were commonly regulated more than two fold at 10 and 16
months. The genes were then clustered according to Euclidian
distance (Data not shown). We restricted our interest to 25
regulated genes after functional analysis and their gene expression
is shown in Figure 3. Moreover, 25 genes were classified using
gene ontology MAS 3 (Table 1). Then six genes, which are
involved in proliferation/apoptosis and cell signaling, were
selected for further validation after gene ontology and bioinfor-
matics analysis. They are shown in bold in Table 1.
QRT-PCR and Protein Analyses of Octreotide-treated
CNDT2.5 Cells Confirm the Upregulation of Six Selected
Genes
QRT-PCR analysis was extended to verify differences in
transcript levels of ANXA1, ARHGAP18, EMP1, GDF15, TGFBR2
and TNFSF15 between CNDT2.5 cells cultured in the absence or
presence of octreotide. Thus, ANXA1, ARHGAP18, EMP1, GDF15,
TGFBR2 and TNFSF15 showed a clear accumulation of transcripts
in response to octreotide treatment (Figure 4). To further verify the
findings from the microarray analysis, we assessed the protein
levels of SSTR 1-5 and the selected genes of interest using western
blot analysis. Western blot analysis detected slight increases in the
levels of SSTR 1, 2 and 3 proteins although not in SSTR5
(Supporting Figure S2) in line with the small increased expression
Table 1. Gene ontology of 25 selected genes from microarray analyses.
Symbol Description Molecular function Biological process Oct/control
ABHD5 abhydrolase domain 5 protein binding lipid metabolism 1.2
ADAMTSL1 ADAMTS-like 1 metallopeptidase activity – 1.5
ANXA1 annexin A1 phospholipase A2 inhibitor cell proliferation 1.3
ARHGAP18 Rho GTPase activating protein 18 GTPase activator activity signal transduction 1.4
ASS1 argininosuccinate synthetase 1 argininosuccinate synthase activity urea cycle 1.5
C1orf110 chromosome 1 open reading frame 110 – – 1.3
CDH13 cadherin 13 calcium binding cell proliferation 1.3
EMP1 epithelial membrane protein 1 – cell proliferation 1.4
ERRFI ERBB receptor feedback inhibitor 1 Rho GTPase activator activity signal transduction 1.2
FLNB filamin B protein binding development 1.1
GDF15 growth differentiation factor 15 growth factor activity signal transduction 1.4
HBEGF heparin-binding EGF-like growth factor epodermal growth factor receptor
binding
signal transduction 21.2
LAMA1 laminin, alpha 1 receptor binding signal transduction 1.3
MAP1LC3C microtubule-associated protein 1
light chain 3
– autophagy 21.3
MICAL2 microtubule associated monoxygenase metal ion binding metabolism 1.2
MYEOV myeloma overexpressed – cell migration 1.3
NEDD4L neural precursor cell, down-regulated 4-like sodium channel regulator activity sodium ion transport 1.3
PDP1 pyruvate dehyrogenase phosphatase 1 protein serine/threonine phosphatase
activity
protein amino acid
dephosphorylation
1.2
PLAU plasminogen activator, urokinase serine-type endopeptidase activity signal transduction 1.3
RGS5 regulator of G-protein signaling 5 GTPase activator activity G-protein coupled receptor
protein signaling pathway
1.0
RUNX2 runt-related transcription factor 2 transcription factor activity negative regulation of
transcription
1.2
S100A10 S100 calcium binding protein A10 receptor binding signal transduction 1.2
SQSTM1 sequestosome 1 SH2 domain binding signaling cascade 1.2
TGFBR2 transforming growth factor, b
receptor II
protein serine/threonine phosphatase
activity
common-partner SMAD
protein phosphorylation
1.3
TNFSF15 tumor necrosis factor
superfamily member 15
tumor necrosis factor receptor binding signal transduction 1.5
Log2 ratio expression between octreotide (Oct) treated CNDT2.5 cells and untreated CNDT2.5 cells (control). Bolded genes were further analyzed.
doi:10.1371/journal.pone.0048411.t001
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of SSTRs from the microarray analysis. In addition, the five
proteins (ANXA1, ARHGAP18, GDF15, TGFBR2 and
TNFSF15) were markedly increased after 10 and 16 months
octreotide treatment as shown in Figure 5A. In contrast, we were
unable to detect EMP1, which in fact has never been detected in
CNDT2.5 cells. The fold changes between untreated and treated
cells are presented in a table for clarity in Figure 5B.
Octreotide-upregulated Transcripts and Encoded
Proteins of CNDT2.5 Cells and SI-NET Tumour Tissue at
Different Stage of Disease
To better understand the octreotide-regulated genes, which
were identified by microarray analyses and QRT-PCR of
CNDT2.5 cells, we next analysed tumour tissue. We first verified
the RNA expression of ANXA1, ARHGAP18, EMP1, GDF15,
TGFBR2 and TNFSF15 using laser capture microdissected (LCM)
tumour cells from 6 frozen blocks as illustrated in Table 2.
Transcript expression in both primary tumours and liver
metastases is evident for all the six genes (Figure 6). We then
investigated protein expression using commercial antibodies for
immunohistochemistry. ANXA1, ARHGAP18, EMP1, GDF15,
TGFBR2 and TNFSF15 protein expression was analysed on tissue
sections from 12 patients as illustrated in Table 2. The proteins
show a variety of different expression pattern and the results are
shown in Figure 7. ANXA 1 is the only protein stained in stroma
cells and not in tumour cells, while the other five stains specifically
either untreated tumour cells or treated ones at different stage of
disease. In addition, the inserts of each panel in the figure show a
weaker staining of the proteins, except for TNFSF15. A clear
summary of the results is shown in Table 3.
Discussion
NET patients require medical management that aims to relieve
symptoms and suppress tumour growth and spread. Somatostatin
and its stable analogues (octreotide, lanreotide and vapreotide)
exert an antiproliferative effect on various normal and cancerous
cells both in vitro and in vivo. Medical approaches in the
management of NETs are limited and SSAs are a valuable
resource to alleviate their symptoms resulting from the secretion of
hormones or vasoactive peptides into the systemic circulation [6].
Moreover, the antitumoral effects of SSAs, recently demonstrated
in SI-NETs [13] have prompted considerable interest in their use
against this kind of rare tumours.
The main aim of our study was to identify potential novel genes,
rather than the SSTRs, behind the effect of octreotide on NET
cells. We used CNDT2.5 cells, as an in vitro model to investigate
how octreotide may alter neuroendocrine cell biology in regard to
tumour cells that express low levels of SSTRs. We studied whether
and how cell growth control and differentiation can occur to the
cells under daily octreotide treatment for up to 16 months, by
applying long-term treatment with high concentration of octreo-
tide. Despite the long treatment, CNDT2.5 cells maintained
sensitivity to the drug. Moreover, they did not show susceptibility
to apoptosis while the growth rate was steadily reduced over time.
The growth capacity was rapidly restored after octreotide
withdrawal (Supporting Figure S1). Furthermore, to better clarify
the mechanism of action behind the reduction of cell growth
induced by octreotide on CNDT2.5 cells, we gene profiled the
cells to investigate variations in transcript levels after long-term
octreotide treatment. By using microarray expression analysis, the
expression levels of several hundred genes can be detected
simultaneously and bioinformatics and gene ontology analyses
suggested that 25 genes are differentially regulated by octreotide
treatment. We choose 6 genes in the list, which were previously
unrelated to octreotide signaling, excluding others for three main
reasons. First, the genes were selected according to the biological
functions inherent to proliferation/apoptosis and cell signaling by
gene ontology. Second, the transcripts are not alternatively spliced
to a large degree, which makes the preparation of QRT-PCR
primers ideal. Third, commercial antibodies were available to
extend the investigation to protein expression both in CNDT2.5
cellular total lysates and tissue specimens. Thus, these genes which
are associated to proliferation/apoptosis and cell signaling may be
involved in mediating octreotide-induced CNDT2.5 cell growth
reduction.
Our results show that different times of octreotide treatment
triggered a progressive increase in transcription of the all selected
Figure 3. Gene expression of CNDT2.5 cells and 1 mM
octreotide treated cells. Microarray analysis detected 25 differen-
tially expressed genes in octreotide treated CNDT2.5 cells compared to
CNDT2.5 untreated cells (control). Upregulated genes are in yellow and
downregulated genes are in blue. Genes were clustered according to
Euclidian distance, as indicated in the figure. Of the 25 genes, 6 were
selected for further analysis and they are indicated by a red asterisk.
doi:10.1371/journal.pone.0048411.g003
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genes (ANXA1, ARHGAP 18, EMP1, GDF15, TGFBR2 and
TNFSF15), without altering the expression levels of SSTRs (Data
not shown) in CNDT2.5 cells. Moreover, we confirmed induced
upregulation by octreotide for most of these genes at the protein
level. Thus, we suggest that octreotide may be effective in
controlling growth of CNDT2.5 cells for a long time without
triggering any resistance during a long treatment. Furthermore,
results indicate that even cells or tissues expressing low levels of
SSTRs, such as those tested here, show significant responses to
octreotide.
In this scenario, our present results reveal a potential role for six
select genes, ANXA1, ARHGAP18, EMP1, GDF15, TGFBR2 and
TNFSF15, which have not been explored hitherto in this field, and
therefore deserve further investigation. ANXA1, EMP1, TGFBR2
and TNFSF15 have major roles in biological processes such as cell
proliferation and apoptosis [30,31,32,33], whereas ARHGAP18
and GDF15 have major roles in signal transduction [34,35].
Moreover, both ARHGAP18 and EMP1 might work as tumour
suppressors [36,37].
Briefly, ANXA1 is a protein involved in adhesion, proliferation,
apoptosis, migration, growth and differentiation [38]. It has also
been proposed that ANXA1 expression may correlate with the
tumorigenesis, of thyroid and gastric cancer, which emphasizes the
importance of ANXA1 in different kinds of cancers [30,39].
ARHGAP18 encodes rho GTPase-activating protein 18, which
belongs to the RhoGAP family and functions as GTPase activator
for the Rho-type GTPases. Notably, the RhoGAP family includes
several tumour suppressors [40] and the role of Rho GTPases in
diverse NETs signaling pathway has been established [35]. EMP1
encodes epithelial membrane protein 1, a multi-pass membrane
protein that plays a role as a biomarker of gefitinib clinical
resistance [41,42]. EMP1 is involved in the EGFR signaling
pathway with an important role in cell proliferation and epithelial
cell differentiation and it is considered important in metastatic
colorectal cancer [43]. GDF15 encodes growth/differentiation
factor 15, a member of the transforming growth factor beta (TGF
beta) superfamily that regulates tissue differentiation [44]. In
addition, this protein has a variety of roles in growth, apoptosis,
survival, proliferation and signaling [45]. TGFBR2 encodes TGF-
beta II receptor, a member of the Ser/Thr protein kinase family,
which is part of the TGFB receptor superfamily [46]. The protein
is a single-pass type I membrane protein, receptor for TGF-beta,
Figure 4. QRT-PCR analysis on CNDT2.5 cells in the absence or presence of 1 mM octreotide. ANXA1, ARHGAP18, EMP1, GDF15, TGFBR2
and TNFSF15 were analysed using total RNA at 1 week (wk), 4 months, 10 months and 16 months (mo) of culture by QRT-PCR. Results were plotted
using the 22DDCt method with b-actin expression (set to 1) from each individual sample as endogenous reference. Plotted results are means6 SD for
triplicate wells. Significance was calculated by Two-Way ANOVA followed by Bonferroni test; comparing with untreated CNDT2.5 cells. *** = p,0.001.
doi:10.1371/journal.pone.0048411.g004
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an important regulator of cell proliferation, differentiation and
extracellular matrix production. Mutations in this gene have been
associated with the development of various types of tumours [47].
Explicitly it has a defined role in colon cancer and a combination
of inactivation of the TGF-3 signaling pathway and expression of
oncogenic Kras leads to formation of invasive intestinal neoplasms
through a beta-catenin-independent pathway [48]. Last,
TNFSF15 encodes a cytokine, which belongs to the tumor
necrosis factor (TNF) ligand family and its second common ID
is VEGI, vascular endothelial cell growth inhibitor. This protein is
abundantly expressed in endothelial cells and never in B or T cells.
Protein expression is inducible by TNF and IL-1 alpha. This
cytokine is a ligand for receptor TNFRSF25 and decoy receptor
TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases,
and acts as an autocrine factor to induce apoptosis in endothelial
cells. This cytokine is also found to inhibit endothelial cell
proliferation, and thus may function as an angiogenesis inhibitor.
However, the complex function in diseases and health is
summarized in a 2011 article, which considers its pivotal role in
cancer-tumor-immonology [49].
However, we were not able to obtain unequivocal evidence that
the six proposed genes have a major role on octreotide direct
effects. Indeed, it is very well known that this drug may have a
capacity to control changes of some structural properties of the
cells via secondary effects. In addition, the in vitro antiangiogenic
effects of somatostatin and its analogues have been previously
shown by studies on melanoma cells, which expressed one or more
SSTR and were treated by using somatostatin or SSAs [20,50].
As far as we know, we are the first group proposing that
octreotide may signal its effects through SSTRs by activating a set
of genes that have not previously been associated to the
conventional octreotide signaling pathway. It is today not known
how downstream events lead to differential expression of the six
described genes. Indeed, we have been treating our in vitro model
up to 16 months, showing that EMP1, GDF15 and TGFBR2 are
modulated after 10 months of treatment. This potentially suggests
that they are not involved at the earlier time point when octreotide
is able to inhibit cell proliferation. Thus, this may imply that
EMP1, GDF15 and TGFBR2 might be either involved in
octreotide indirect effects or being pivotal in opposing cell growth
control via a downstream network. However, the six genes
Figure 5. ANXA1, ARHGAP18, EMP1, GDF15, TGFBR2 and TNFSF15 Western blot analysis. CNDT2.5 cells cultured in the absence or
presence of 1 mM octreotide were collected at 1 week (wk), 4 months, 10 months and 16 months (mo) to prepare total lysates. Octreotide induces
protein expression level of octreotide treated CNDT2.5 cells for 10 and 16 months compared to untreated cells (5A). b-actin was used as endogenous
control. Fold changes are illustrated in 5B.
doi:10.1371/journal.pone.0048411.g005
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represent new, valuable tools for the identification of novel
potential biomarkers or therapeutically relevant targets. Hence,
the whole-transcript expression analysis of CNDT2.5 cells offers a
powerful and informative resource for detecting variation in gene
expression between non-treated and long-term octreotide-treated
CNDT2.5 cells. Most importantly, extension of our analysis to
primary SI-NET and liver metastases showed that these genes
encode proteins in tumour tissues. Although it is difficult to access
to the right number of tumour specimens to translate the results
in vitro to clinical results, we strongly believe that the novel
potential mechanisms used by octreotide to control NET biology
should be investigated.
Thus, octreotide may signal through alternative mechanisms
that require expression of SSTRs in combination with different
genes, which may activate a potential novel framework, which is
not fully understood. However, our transcriptomic analysis
detected 6 novel genes, which may encode proteins able to cross
talk. Thus, SSTRs, ANXA1, ARHGAP18, EMP1, GDF15, TGFBR2
and TNFSF15 genes and encoded proteins may have a potential
role in controlling cell growth and differentiation in human NET
cells by octreotide. Moreover, investigating this new potential
framework help our understanding about why patients get relief
from SSA therapy when they do not initially overexpress high
amount of SSTRs [51,52]. The newly detected proteins control
many different cellular mechanisms. Thus, further analyses are
necessary to fully understand the new mechanisms of octreotide to
control NET cells growth and differentiation. Ideally, an animal
model may clarify better our hypothesis.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Moreover, this study was approved
by the regional Ethical Committee at the Clinic of Endocrine
Oncology, Uppsala University Hospital, Sweden. All the partic-
ipants provided written consent for studying the tissue samples and
eventually to publish new obtained scientific data. The study was
performed in accordance with the regional Ethical Committee at
the Clinic of Endocrine Oncology, Uppsala University Hospital,
Sweden (approval number: Dnr 2011/426).
Table 2. Small intestine neuroendocrine tumour specimens and analyses.
Patient Sex/Age* Treatment Type Tissue Analysis
1 M/70 Untreated Primary Ileum QRT-PCR, LCM (FS)
2 F/63 Untreated Primary Ileum QRT-PCR, LCM (FS)
3 F/63 Untreated Primary Ileum QRT-PCR, LCM (FS), IHC (PET)
4 M/54 Untreated Primary Ileum IHC (PET)
5 F/59 Untreated Primary Ileum IHC (PET)
6 F/68 Untreated Metastases Liver IHC (PET)
7 M/60 Untreated Metastases Liver IHC (PET)
8 F/71 Untreated Metastases Liver IHC (PET)
9 F/57 SSA+IFN Primary Ileum IHC (PET)
10 F/58 SSA+IFN Primary Ileum IHC (PET)
11 F/52 SSA+IFN Primary Ileum IHC (PET)
12 F/67 SSA+IFN Metastases Liver QRT-PCR, LCM (FS), IHC (PET)
13 F/65 SSA+IFN Metastases Liver QRT-PCR, LCM (FS)
14 F/76 SSA+IFN Metastases Liver QRT-PCR, LCM (FS)
15 M/61 SSA Metastases Liver IHC (PET)
16 F/44 SSA+IFN Metastases Mesentery IHC (PET)
Age at the time of operation (Age*); Somatostatin Analogues (SSA); Interferon a (IFN).
Laser Capture Microdissection (LCM); Frozen Specimen (FS); Paraffin-Embedded Tissue (PET).
doi:10.1371/journal.pone.0048411.t002
Table 3. Result of Immunohistochemistry on paraffin
embedded SI-NET specimens.
Protein P L M Positive Staining
UT T UT T T
ANXA1 3/3– 3/3– 3/3– 2/2– 1/1– 0/12
ARHGAP18 2/3+++ 2/3++ 1/3+++ 2/2+++ 1/1++ 12/12
1/3++ 1/3+ 2/3++
EMP1 1/3+++ 3/3+++ 3/3+++ 1/2+++ 1/1+++ 12/12
2/3++ 1/2++
GDF15 1/3+++ 3/3++ 1/3++ 1/2+++ 1/1++ 12/12
1/3++ 2/3+ 1/2+
1/3+
TGFBR2 2/3+ 3/3+ 1/3+ 1/2+ 1/1++ 8/12
1/3– 2/3– 1/2–
TNFSF15 1/3+++ 2/3+++ 1/3+++ 1/2+ 1/1+ 11/12
1/3++ 1/3++ 2/3+ 1/2–
1/3+
Primary tumour (P); Liver metastases (L); Mesentery metastases (M); Untreated
(UT); Treated (T).
Intensity in.50% of tumour cells: +++ strong, ++moderate, + weak, – negative.
doi:10.1371/journal.pone.0048411.t003
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Human NET Cell Lines and Media
CNDT2.5, KRJ-1 and QGP-1 were gifts from Prof. L.M. Ellis,
MD Anderson Cancer Center, Houston, TX, USA, Prof. I.M.
Modlin, Yale University, New Haven, CT, USA and Prof. B.
Ericsson, Uppsala University Hospital, Uppsala, Sweden respec-
tively. Moreover, these cells were previously used for scientific
studies, which have been published as You can see in the follow
references [27,28,29]. The human lung carcinoids cell lines NCI-
H720 and NCI-H727 were from ATCC (LGC Promochem,
Sweden). The cells were cultured at 37uC and 5% CO2-humidified
atmosphere in culture media as previously reported [27,28,29,53].
Tissue Samples
The tissue samples included in the study have a histopatholog-
ically confirmed diagnosis of SI-NETs. Snap-frozen specimens
from 6 patients were used to isolate total RNA from laser capture
microdissected (LCM) tumour cells. Moreover, formalin fixed
paraffin-embedded tissues from 12 patients were used for
immunohistochemistry (IHC). Patients’ information is summarized
in Table 2. Permission to collect tumour specimens was approved
by the regional Ethical Committee at the Uppsala University
Hospital (Dnr 2011/426).
Laser Capture Microdissection of NET Cells
Snap-frozen specimens from three untreated primary tumours
and three SSA+IFN treated liver metastases were cut in 8-mm
sections by a microtome cryostat (Leica, Wetzlar, Germany) and
adhered to polyethylene-naphtalate membrane frame slides
(Applied Biosystems, Life Technologies, Carlsbad, California,
USA). Primary tumour cells and liver metastatic cells were isolated
by ArcturusXT Microdissection system (Applied Biosystems)
according to the manufacturer’s instructions.
RNA Extraction From Cell Lines and Laser Capture
Microdissected Tumour Cells
Total RNA was isolated from five human neuroendocrine
cancer cell lines with PARIS Kit (Applied Biosystems) according to
the manufacturer’s instructions. RNAqueous Micro Kit (Applied
Biosystems) was used to prepare total RNA from laser capture
microdissected tumour cells. RNA quantity and quality was always
verified by using the RNA 6000 Nano Kit/RNA 6000 Pico Kit
and the Agilent 2100 Bioanalyzer (Agilent technologies, Wald-
bronn, Germany).
Microarray Data Analysis and Data Mining
About one microgram of total RNA per each cell line described
above was sent to the Uppsala Array Platform, Uppsala University
Hospital, Uppsala, Sweden. Total RNA was hybridized onto the
Affymetrix Human Gene 1.0 ST Array (Affymetrix, Santa Clara,
CA, USA) and processed according to Affymetrix technical
protocols. Scanned images of microarray chips were analysed by
the GeneChip Operating Software (Affymetrix). Untreated
CNDT2.5 cells and treated CNDT2.5 cells were always cultured
at the same time. We profiled gene expression of untreated human
neuroendocrine cancer cells CNDT2.5 and 1 mM octreotide
treated CNDT2.5 cells after 10 and 16 months of culture. The raw
data were normalized using RMA algorithm. This analysis was
performed with the MeV software (www.tm4.org) [54]. Before
comparing the effect of long time (10 months and 16 months)
octreotide treatment on CNDT2.5 cells gene expression, micro-
array raw data were normalized using FARMS normalization
algorithm as implemented in XPS, package (R/Bioconductor:
www.bioconductor.org). Significantly marked genes as informative
with a present call by I/NI-calls algorithm were kept for further
fold change analysis between treated and untreated cells. A
hierarchical clustering algorithm was applied to group genes and
samples according to similarities in expression. Genes differentially
expressed were clustered using Euclidian distance with average
linkage clustering (genes and samples). Gene function based on
gene ontology analysis was performed by using IHOP - Gene
Model (www.ihop-net.org/UniPub/iHOP/) and MAS 3(http://
bioinfo.capitalbio.com/mas3/).
Figure 6. Gene expression of novel detected genes from laser capture microdissected tumour cells. Total RNA from microdissected
tumour cells of three primary tumour (P) specimens and three liver metastases (L) were analysed by QRT-PCR. Results are plotted using the 22DDCt
method with b-actin expression (set to 1) from each individual sample as endogenous reference. Plotted results are means6 SD from triplicate wells.
doi:10.1371/journal.pone.0048411.g006
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Cell Proliferation Assay
Spectrophotometric quantification of cell proliferation was
measured by using the metabolic proliferation reagent WST-1
(Roche Applied Science, Mannheim, Germany) according to the
manufacturer’s instructions. The principle of this assay relies on
the cleavage of the stable tetrazolium salt WST-1 to a soluble
formazan by a complex enzymatic cellular mechanism. This
bioreduction mainly depends on the glycolytic production of
NAD(P)H in viable cells. Thus, the amount of formazan dye
formed directly correlates to the number of metabolically active
cells in the culture. CNDT2.5 cellswere cultured in the absence
and presence of otreotide for 1 week, 4, 10 and 16 months. We
Figure 7. Immunohistochemistry of ANXA1, ARHGAP18, EMP1, GDF15, TGFBR2 and TNFSF15. Formalin-fixed paraffin-embedded tissue
sections from 12 SI-NET patients at different stage of disease were used for the staining by using commercial antibodies. Three untreated primary
tumours, 3 treated primary tumours, 3 untreated liver metastases, 2 treated liver metastases (L) and 1 treated mesentery metastasis (M). The results
show a variety of specific pattern of expression of the different proteins, which are described in the Result paragraph. However, they clearly show the
presence of 5 of the 6 selected encoded proteins in the tumor cells of SI-NET slides. Bar = 50 mm.
doi:10.1371/journal.pone.0048411.g007
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first performed WST-1 assay for each time point. Then we
repeated the assay two times using cells frozen at 1 week, 4, 10 and
16 months. Octreotide was used at the concentration of 1 mM and
cells were seeded in 96-well plates 100 mL/well at a density of
1.26103 cells per well. Moreover, cells were cultured in the
presence or absence of 1 mM octreotide for 1 week to evaluate cell
proliferation. Cells were then incubated for 1 h at 37uC in a 5%
CO2 atmosphere in the presence of metabolic reagent WST-1
(10 mL/well). The absorbance of the samples against a background
control as blank (media) was measured at 450 nm by using a
Multiskan Ascent microplate (ELISA) reader (Thermo Scientific,
Rockford, IL, USA). Cell proliferation was calculated as a
percentage of untreated CNDT2.5 cells. WST-1 data were plotted
using the results from three independent wells.
QRT-PCR
About 1 mg of total RNA per sample was converted to cDNA
with iScript cDNA synthesis Kit (Bio-Rad, Hercules, CA, USA).
Briefly, to estimate the starting copy number of cDNA, sample
signal was compared with that generated with a specific standard
curve containing 1, 101, 102, 103, 104, 105 and 106 copies of
synthetic cDNA template for each transcript of interest run on the
same plate. QRT-PCR verified mRNA levels of all SSTR-
subtypes have been recently reported [55]. Results are expressed
as copies of SSTR per copies of b-actin. QRT-PCR primers and
amplicons are described in Supporting Table S2. ANXA1,
ARHGAP18, EMP1, GDF15, TGFBR2 and TNFSF15 were
measured using Stratagene Mx3005P real time PCR System
(Agilent technologies) and brilliant SYBR Green QPCR Master
Mix (Agilent technologies). The data were evaluated by the
22DDCT method [56] using the mRNA level of b-actin (set to 1).
QRT-PCR primers and amplicons are described in Supporting
Table S3.
Western Blot Analysis
CNDT2.5 cells were cultured in the absence or presence of
octreotide 1 mM and total protein lysates were collected at 1 week,
4, 10 and 16 months. Whole-cell protein lysates were extracted by
using radio-immunoprecipitation assay buffer. Cells were at 70%
to 80% confluence as previously described [27]. Protein concen-
trations were determined using Coomassie-Plus Better BradFord
Assay (Thermo Scientific). Aliquots of 70 mg were resolved by
precast any kD Mini-PROTEAn TGX gels (Bio-Rad) and
transferred to 0.45-mm nitrocellulose membranes (Bio-Rad).
Benchmark pre-stained protein ladder (Invitrogen, Carlsbad,
California, USA) was used to calculate the apparent size of
proteins. The membranes were blocked with Western Blocking
Reagent (Roche Applied Science) overnight and then blotted with
the primary antibody overnight at 4uC. Then they were washed
and incubated with the horseradish peroxides-conjugated (HRP)
secondary antibody for 1 h at room temperature and washed
again. The blots were visualized with Lumi-Light Western Blotting
Substrate (Roche Applied Science). Monoclonal mouse anti-
human ANXA1 (1:5000, BD-Transduction Laboratories, Franklin
Lakes, NJ, USA), polyclonal rabbit anti-human ARHGAP18
(1:250, Abgent, San Diego, CA, USA), polyclonal mouse anti-
human EMP1 (1:250, Abnova, Taipei, Taiwan), polyclonal rabbit
anti-human GDF15 (1:250, Atlas Antibodies, Stockholm, Swe-
den), polyclonal goat anti-human TGFBR2 (1:250, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), polyclonal goat anti-
human TNFSF15 (1:500, R&D Systems, Minneapolis, MN, USA),
polyclonal rabbit anti-human SSTR1 (1:5000, Santa Cruz
Biotechnology), polyclonal rabbit anti-human SSTR2 (1:4000,
Thermo Scientific), polyclonal rabbit anti-human SSTR3 and
SSTR5 (1:4000 and 1:5000, gifts from Frank Leu [19], polyclonal
goat anti-human b-actin and HRP donkey anti-goat (1:5000,
Santa Cruz Biotechnology) and HRP anti-mouse and anti-rabbit
(1:5000, Amersham Biosciences, Buckinghamshire, England)
antibodies were used to detect the different proteins.
Immunohistochemistry
We selected paraffin-embedded tissue slides from 12 patients
(Table 2) to investigate the differentially expressed markers. We
used anti-human ANXA1 (1:1000), anti-human ARHGAP18
(1:500), anti-EMP1 (1:500), anti-human GDF15 (1:100), a
different polyclonal rabbit anti-human TGFBR2 (1:500) from
Abbiotec, San Diego, CA, USA and a different polyclonal rabbit
anti-human TNFSF15 (1:1000), from Acris Antibodies, Herford,
Germany. The staining was performed as described elsewhere
[57]. Results were evaluated using Axiophot light microscope and
AxioVision Rel.4.5 software (Carl Zeiss AG, Oberkochen,
Germany).
Statistical Analysis
Results are shown as mean 6 SD. All the experiments were
performed at least in triplicate. The statistical significance of the
difference between two groups was evaluated by two-tailed
Student’s t-test or Two-Way ANOVA followed by Bonferroni test
using GraphPad Prism 5 (Graph Pad, Software, La Jolla CA,
USA); p value ,0.05 is considered significant.
Supporting Information
Figure S1 CNDT2.5 cells growth in the presence of 1 mM
octreotide for 15 or 16 weeks. Cells were cultured in the
absence or presence of 1 mM octreotide. Cell proliferation rate was
converted to a percentage of the mean value relative to the
untreated CNDT2.5 cells, set to 100% and results represent means
6 SD from triplicate wells. Significance was calculated by student
t-test, comparing with untreated CNDT2.5 cells. * p,0.05, **
p,0.001.
(TIF)
Figure S2 SSTR1, SSTR2, SSTR3 and SSTR5 protein
expression. CNDT2.5 cells were cultured in the absence or
presences of 1 mM octreotide (oct). They were collected at 1 week
(wk) and 16 months (mo) for preparing total lysates and
performing western blot analysis. b-actin was used as endogenous
control. Western blot results are shown on the left and the table
shows the protein fold change on the right.
(TIF)
Table S1 Microarray data of somatostatin receptors 1–5 on
CNDT 2.5 cells.
(DOC)
Table S2 Primer pairs of SSTRs used for QRT-PCR analysis.
(DOC)
Table S3 Primer pairs of selected genes used for QRT-PCR
analysis.
(DOC)
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